AI + EXCLUSIVE DATA

AI identifies M&A opportunities from proprietary sources

Our AI analyzes exclusive acquisition data to predict which merged companies need YOUR integration capabilities.

10-25 M&A leads daily • Tech stack analysis • Integration scoring

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + exclusive M&A intelligence

✓Post-merger opportunity analysis

INDUSTRY FIRST

Sherlock Biosciences Acquires Sense Biodetection Advancing Crispr-Based Diagnostics For Consumers

Feb 01, 2023•over 2 years ago

Acquiring Company

Sherlock Biosciences

Acquired Company

Sense Biodetection

Boston

BostonBiotechnologyHealth Care

Description

Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator. The acquisition accelerates Sherlock's go-to-market strategy by adding Sense's VerosTM instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be used anytime, anywhere. Terms of the acquisition are not being disclosed.

Company Information

Company

Sherlock Biosciences

Location

40 GUEST STREET

Boston, Massachusetts, United States

About

Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Through our engineering biology tools, CRISPR-based SHERLOCKTM and synthetic biology-based INSPECTRTM, we are bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.

Company News

(10 articles)

Mon, 24 Feb 2025 08:00:00 GMT

CRISPR-Based Diagnostics: The Future of Disease Detection - News-Medical

Tue, 08 Mar 2022 08:00:00 GMT

Sherlock Bio raises $80 million to develop CRISPR-based diagnostics - Reuters

Thu, 30 May 2024 07:00:00 GMT

Sherlock Biosciences Starts Clinical Trial of Disposable Molecular STI Test vs. Central Lab Tests - CRISPR Medicine News

Tue, 08 Mar 2022 08:00:00 GMT

Sherlock Biosciences Raises $80 Million in Series B Financing to Democratize At-Home Diagnostic Testing - PR Newswire

Wed, 01 Feb 2023 08:00:00 GMT

Sherlock Biosciences nabs Sense Biodetection to expand CRISPR diagnostic reach - Fierce Biotech

Wed, 20 Jul 2022 07:00:00 GMT

Sherlock Biosciences Is Cracking At-Home and Field Diagnostics - Genetic Engineering and Biotechnology News

Tue, 08 Mar 2022 08:00:00 GMT

Sherlock Bio raises $80 million to apply COVID-testing tech to other diseases - The Boston Globe

Wed, 01 Feb 2023 08:00:00 GMT

Sherlock Biosciences Acquires Sense Biodetection to Commercialize Disposable CRISPR-Based Diagnostics: - Mary Ann Liebert, Inc.

Thu, 21 Mar 2019 07:00:00 GMT

With Launch Of New CRISPR Company, Competition Extends To Diagnostics - Forbes

Thu, 21 Mar 2019 07:00:00 GMT

Sherlock Biosciences licenses Wyss technology to create affordable molecular diagnostics - Harvard Office of Technology Development

FundzWatch™ Score

High M&A Activity

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed